Different protein expression in normal and dysfunctional platelets from uremic patients

Journal of Nephrology

Volumn 23, Issue 1, 2010, Pages 90-101

  Marques, María ^a   Sacristán, Daniel ^a   Mateos Cáceres, Petra J ^a   Herrero, José ^a   Arribas, María J ^a   González Armengol, Juan J ^a   Villegas, Ana ^a   Macaya, Carlos ^a   Barrientos, Alberto ^a   López Farré, Antonio J ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

PFA 100; Platelets; Protein expression; Proteomic; Uremia

Indexed keywords

ACTIN INTERACTING PROTEIN 1; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BINDING PROTEIN; CALCIUM ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUTATHIONE TRANSFERASE; HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTEGRIN IIB; PEROXIREDOXIN 6; UNCLASSIFIED DRUG; URIC ACID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DOWN REGULATION; DYSLIPIDEMIA; FEMALE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; HYPERTENSION; MALE; MEGAKARYOCYTE; PROTEIN EXPRESSION; THROMBOCYTE COUNT; THROMBOCYTE DYSFUNCTION; THROMBOCYTE FUNCTION; UPREGULATION; UREMIA; URIC ACID BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD18; BLOOD PLATELETS; BLOOD PROTEINS; CELL COMMUNICATION; CREATININE; CYTOSKELETON; ENERGY METABOLISM; FEMALE; GLUTATHIONE TRANSFERASE; HUMANS; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; OXIDATIVE STRESS; PEROXIREDOXIN VI; PROTEOMICS; UREMIA; URIC ACID;

EID: 77249148854     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Morgagni GB. Opera omnia ex typographia remondiniana. Venezia, Italy:1764.
2. Bizzozero J. Uber einen neven: form bestandtheil des blutes und die rolle bie der thrombose un Blutgerinnung. Virchows Arch. 1882;90:261.
3. Remuzzi G. Bleeding in renal failure. Lancet. 1988;1:1205-1208.
4. Dinkar K, Malhotra D. Platelet dysfunction and end-stage renal disease. Semin Dial. 2006;19:317-322.
5. Sohal AS, Gangji AS, Crowther MA, Treleaven D. Uremic bleeding: pathophysiology and clinical risk factors. Thromb Res. 2005;118:417-422.
6. Remuzzi G, Livio M, Marchiaro G, Mecca G, De Gaetano G. Bleeding in renal failure: altered platelet function in chronic uraemia only partially corrected by haemodialysis. Nephron. 1978;22:347-353.
7. Smith MC, Dunn MJ. Impaired platelet thromboxane production in renal failure. Nephron. 1981;29:133-137.
8. Remuzzi G, Benigni A, Dodesini P, et al. Reduced platelet thromboxane formation in uremia: evidence for a functional cyclooxygenase defect. J Clin Invest. 1983;71:762-768.
9. Ware JA, Clark BA, Smith M, Salzman EW. Abnormalities of cytoplasmic Ca+2 in platelets from patients with uremia. Blood. 1989;73:172-176.
10. Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. Semin Thromb Hemost. 2004;30:579-589.
11. Escolar G, Díaz-Ricart M, Cases A. Uremic platelet dysfunction: past and present. Curr Hematol Rep. 2005;4:359-367.
12. Rabine SF, Molinas F. The role of phenol and phenolic acids on the thrombocytopathy and defective platelet aggregation of patients with renal failure. Am J Med. 1970;49:346-351.
13. Eknoyan G, Brown CH III. Biochemical abnormalities of platelets in renal failure: evidence for decreased platelet serotonin, adenosine diphosphate and Mg-dependent adenosine triphosphatase. Am J Nephrol. 1981;1:17-23.
14. Mezzano D, Tagle R, Panes O, et al. Hemostatic disorder of uremia: the platelet defect, main determinant of the prolonged bleeding time, is correlated with indices of activation of coagulation and fibrinolysis. Thromb Haemost. 1996;76:312-321.
15. García A, Zitzmann N, Watson SP. Analyzing the platelet proteome. Semin Thromb Hemost. 2004;30:485-489.
16. Kotzailias N, Elwischger K, Sycha T, et al. Clopidogrel-induced platelet inhibition cannot be detected by the platelet function analyzer-100 system in stroke patients. J Stroke Cerebrovasc Dis. 2007;16:199-202.
17. Escolar G, Cases A, Viñas M et al. Evaluation of acquired dysfunctions in uremic and cirrhotic patients using the platelet function analyzer (PFA-100): influence of hematocrit elevation. Haematologica. 1999;84:614-619.
18. López-Farré A, Caramelo C, Esteban A, et al. Effects of aspirin on platelet-neutrophil interactions: role of nitric oxide and endothelin-1. Circulation. 1995;91:2080-2088.
19. Mateos-Cáceres PJ, García-Méndez A, López Farré A, et al. Proteomic analysis of plasma from patients during an acute coronary syndrome. J Am Coll Cardiol. 2004;44:1578-1583.
20. López-Farré AJ, Mateos-Cáceres PJ, Sacristán D, et al. Relationship between vitamin D binding protein and aspirin resistance in coronary ischemic patients: a proteomic study. J Proteome Res. 2007;6:2481-2487.
21. Fox JE. Identification of actin-binding protein as the protein linking the membrane skeleton to glycoproteins on platelet plasma membranes. J Biol Chem. 1985;260:11970-11977.
22. Walkowiak B, Kaminska M, Okrój W, et al. The blood platelet proteome is changed in uremic patients. Platelets. 2007;18:386-438.
23. Escolar G, Díaz-Ricart M, Cases A, Castillo R, Ordinas A, White JG. Abnormal cytoskeletal assembly in platelets from uremic patients. Am J Pathol. 1993;143:823-831.
24. Benigni A, Boccardo P, Galbusera M, et al. Reversible activation defect of the platelet glycoprotein IIb-IIIa complex in patients with uremia. Am J Kidney Dis. 1993;22:668-676.
25. Kaw D, Malhotra D. Platelet dysfunction and end-stage renal disease. Semin Dial. 2006;19:317-322.
26. Kozek-Langenecker SA, Masaki T, Mohammad H, Green W, Mohammad SF, Cheung AK. Fibrinogen fragments and platelet dysfunction in uremia. Kidney Int. 1999;56:299-305.
27. Kaplan B, Cojocaru M, Unsworth E, Knecht A, Martin BM. Search for peptidic "middle molecules" in uremic sera: isolation and chemical identification of fibrinogen fragments. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;796:141-153.
28. Thekkedath UR, Chirananthavat T, Leypoldt JK, Cheung AK, Mohammad SF. Elevated fibrinogen fragment levels in uremic plasma inhibits platelet function and expression of glycoprotein IIb-IIIa. Am J Hematol. 2006;81:915-926.
29. Mannucci PM, Remuzzi G, Pusineri F, et al. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med. 1983;308:8-12.
30. Salvati F, Liani M. Role of platelet surface receptor abnormalities in the bleeding and thrombotic diathesis of uremic patients on hemodialysis and peritoneal dialysis. Int J Artif Organs. 2001;24:131-135.
31. Himmelfarb J, Hakim RM. Oxidative stress in uremia. Curr Opin Nephrol Hypertens. 2003;12:593-598.
32. Tepel M, Echelmeyer M, Orie NN, Zidek W. Increased intracel lular reactive oxygen species in patients with end-stage renal failure: effect of hemodialysis. Kidney Int. 2000;58:867-872.
33. Zanetti M, Barazzoni R, Guarnieri G. Inflammation and insulin resistance in uremia. J Ren Nutr. 2008;18:70-75.
34. Vaziri ND. Oxidative stress in uremia: nature, mechanisms, and potential consequences. Semin Nephrol. 2004;24:469-473.
35. Vaziri ND, Lin CY, Farmand F, Sindhu RK. Superoxide dismutase, catalase, glutathione peroxidase and NADPH oxidase in lead-induced hypertension. Kidney Int. 2003;63:186-194.
36. Ceballos-Picot I, Witko-Sarsat V, Merad-Boudia M, et al. Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radic Biol Med. 2004;21:845-853.
37. Manevich Y, Fisher AB. Peroxiredoxin 6, a 1-Cys peroxiredoxin, functions in antioxidant defense and lung phospholipid metabolism. Free Radic Biol Med. 2003;38:1422-1423.
38. Lee CK, Kim HJ, Lee YR, et al. Analysis of peroxiredoxin decreasing oxidative stress in hypertensive aortic smooth muscle. Biochim Biophys Acta. 2007;1774:848-885.
39. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA. 2000;283:2404-2410.
40. Vaccarino V, Krumholz HM. Risk factors for cardiovascular disease: one down, many more to evaluate. Am Intern Med. 1999;131:62-63.
41. Castillo R, Lozano T, Escolar G, Revert L, López J, Ordinas A. Defective platelet adhesion on vessel subendothelium in uremic patients. Blood. 1986;68:337-342.
42. Zwaginga JJ, IJsseldijk MJ, de Groot PG, Vos J, de Bos Kuil RL, Sixma JJ. Defects in platelet adhesion and aggregate formation in uremic bleeding disorder can be attributed to factors in plasma. Arterioscler Thromb. 1991;11:733-744.
43. Vanholder R, De Smet R, Glorieux G et al. Review on uremic toxins: classification, concentration, and interindividual variability, Kidney Int. 200;63: 1934-1943.
44. Horowitz HI, Stein IM, Cohen BD, White JG. Further studies on the platelet-inhibitory effect of guanidinosuccinic acid and its role in uremic bleeding. Am J Med. 1970;49:336-345.
45. Kieffer N, Guichard J, Farcet JP, Vainchenker W, Breton-Gorius J. Biosynthesis of major platelet proteins in human blood platelets. Eur J Biochem. 1987;164:189-195.
46. Stenberg PE, Hill RJ. Platelets and megakaryocytes. In: Lee G, Foerster J, Lukens J, eds. Wintrobe's clinical hematology. Baltimore: Williams & Wilkins; 1999: 615-660.
47. Lindemann S, Tolley ND, Dixon DA, et al. Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J Cell Biol. 2001;154:485-490.
48. Joist JH, Remuzzi G, Mannucci PM. Abnormal bleeding and thrombosis in renal disease. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and thrombosis: basic principles and clinical practice. Philadelphia, PA: Lippincott; 1994:921-935.
49. Zwaginga JJ. Hemodialysis, erythropoietin and megakaryo-cytopoiesis: factors in uremic thrombocytopathy and thrombophilia. J Thromb Haemost. 2004;2:1272-1274.
50. Fernandez F, Goudable C, Sie P, et al. Low haematocrit and prolonged bleeding time in uraemic patients: effect of red cell transfusions. Br J Haematol. 1985;59:139-148.
51. Howard AD, Moore J Jr, Welch PG, Gouge SF. Analysis of the quantitative relationship between anemia and chronic renal failure. Am J Med Sci. 1989;297:309-313.